Amarin secures US formulation patent for fish oil pill, fueling more talk on a pharma deal
This article was originally published in Scrip
Executive Summary
Amarin can now point to a success on its patent wrangling, making the firm a more attractive takeover target. The company said the US Patent and Trademark Office has published a notice of allowance for its very significant composition/formulation patent (the ‘598) for its fish oil-derived pill, AMR101, which is a semi-synthetic, 96% ultra-pure ethyl ester of eicosapentaenoic acid (EPA) in a capsule without doxasahexanoic acid (DHA).